Roche: positive long-term data in lymphoma

(CercleFinance.com) - On Tuesday, Roche unveiled encouraging long-term data on its two lymphoma treatments, Columvi and Lunsumio, at a congress in the US.


The Swiss pharmaceutical group reports that, after three years of follow-up in a phase II trial, Columvi achieved a 40% complete response rate in patients with relapsed or refractory diffuse large B-cell lymphoma enrolled in the trial.

According to these results, the majority of patients who were in complete remission at the end of treatment remained so after two years.

Meanwhile, long-term data from the Lunsumio Phase II trial showed that 64% of patients with relapsed or refractory follicular lymphoma were still alive, or had not progressed, after 45 months of follow-up.

These findings were presented at the American Society of Hematology (ASH) annual meeting in San Diego, California.


Copyright (c) 2024 CercleFinance.com. All rights reserved.